Literature DB >> 36072193

Effect of the COVID-19 Pandemic Lockdown on the Management of Diabetic Retinopathy: A Cross-Sectional Study.

Vaishali Prajapati1, Krishna Shah1, Dhruvi Shah1, Mayur B Wanjari2, Deepika Singhal1.   

Abstract

Introduction Worldwide, diabetic retinopathy (DR) is one of the leading causes of vision loss. Early treatment and screening for DR have a major role in reducing the rate of the disease and the coronavirus disease 2019 (COVID-19) pandemic-related restrictions have altered real-world practice patterns in managing DR. Aims and objectives To evaluate the impact of the COVID-19 pandemic on the management of DR amongst patients presenting to a tertiary eye care center in Gujarat, India. Methods This is a cross-sectional study comparison of ophthalmic findings of 72 patients who presented to a tertiary care hospital with the manifestation of DR before and after the COVID-19 outbreak and subsequent lockdown. All the patients underwent detailed ophthalmic examinations, including optical coherence tomography (OCT) and fundus fluorescein angiography (FFA). Results The mean age of participants was 54.5 years, with the mean duration of diabetes being five years since first detected. Diabetes was present in 26 patients out of 72. The number of follow-up visits to an ophthalmologist before COVID-19 was at least every one to three months, which significantly decreased after the lockdown of COVID-19. We found a significant progression of DR and clinically significant macular edema (CSME) in patients with diabetes. Before COVID-19, there were two mild non-proliferative diabetic retinopathy (NPDR), seven moderate NPDR, 15 severe NPDR, and 15 very severe NPDR, which were increased post lockdown to three, nine, 27, and 21, respectively. The proliferative diabetic retinopathy (PDR) vitreous hemorrhage (VH) and tractional retinal detachment (TRD) were also increased to 12 after lockdown as compared to only six before the COVID-19 lockdown. The causes for progression are inability to attend regular check-ups, inability to take proper treatment of diabetes and DR, poor control of diabetes, episode of COVID-19, history of high dose of steroid use, poor kidney function, and not knowing that there is a progression of the disease. A common reason for not visiting an ophthalmologist was fear of the unknown due to COVID-19. Conclusions COVID-19 has severely impacted the routine follow-up of DR and, in the subsequent years, there might be an increased incidence of severe outcomes due to DR. The second wave of COVID-19 and its lockdown have had very significant effects on the visual outcome of untreated DR patients.
Copyright © 2022, Prajapati et al.

Entities:  

Keywords:  covid-19; covid-19 fallout; csme; diabetic retinopathy; etdrs classification; non-proliferative diabetic retinopathy (npdr); npdr

Year:  2022        PMID: 36072193      PMCID: PMC9436826          DOI: 10.7759/cureus.27623

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  16 in total

Review 1.  Diabetic retinopathy.

Authors:  David A Antonetti; Ronald Klein; Thomas W Gardner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

2.  Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.

Authors:  Jeffrey S Heier; Jean-François Korobelnik; David M Brown; Ursula Schmidt-Erfurth; Diana V Do; Edoardo Midena; David S Boyer; Hiroko Terasaki; Peter K Kaiser; Dennis M Marcus; Quan D Nguyen; Glenn J Jaffe; Jason S Slakter; Christian Simader; Yuhwen Soo; Thomas Schmelter; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Carola Metzig; Frank G Holz
Journal:  Ophthalmology       Date:  2016-09-17       Impact factor: 12.079

3.  Clinical Experience in the Administration of Intravitreal Injection Therapy at a Tertiary University Hospital in Jordan During the COVID-19 Lockdown.

Authors:  Omar A Saleh; Hisham Jammal; Noor Alqudah; Asem Alqudah; Nakhleh Abu-Yaghi
Journal:  Clin Ophthalmol       Date:  2020-08-24

4.  Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis.

Authors:  Matteo Fallico; Andrea Maugeri; Andrew Lotery; Antonio Longo; Vincenza Bonfiglio; Andrea Russo; Teresio Avitabile; Alfredo Pulvirenti; Claudio Furino; Gilda Cennamo; Martina Barchitta; Antonella Agodi; Michele Reibaldi
Journal:  Acta Ophthalmol       Date:  2020-12-16       Impact factor: 3.761

5.  Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19.

Authors:  Lydia G Stone; Adele Devenport; Irene M Stratton; James S Talks
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-07-25       Impact factor: 3.117

Review 6.  Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic.

Authors:  Jean-François Korobelnik; Anat Loewenstein; Bora Eldem; Antonia M Joussen; Adrian Koh; George N Lambrou; Paolo Lanzetta; Xiaoxin Li; Monica Lövestam-Adrian; Rafael Navarro; Annabelle A Okada; Ian Pearce; Francisco J Rodríguez; David T Wong; Lihteh Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-04-23       Impact factor: 3.117

7.  Effect of COVID-19-associated lockdown on the metabolic control of patients with type 2 diabetes.

Authors:  Ourania Psoma; Eleftheria Papachristoforou; Aikaterini Kountouri; Kostantinos Balampanis; Athena Stergiou; Vaia Lambadiari; Stavros Liatis; Vasilis Tsimihodimos
Journal:  J Diabetes Complications       Date:  2020-10-07       Impact factor: 2.852

8.  Effect of COVID-19-Associated Lockdown on Patients With Diabetic Retinopathy.

Authors:  Irini Chatziralli; Eleni Dimitriou; Dimitrios Kazantzis; Genovefa Machairoudia; Georgios Theodossiadis; Panagiotis Theodossiadis
Journal:  Cureus       Date:  2021-05-04

Review 9.  Diabetic retinopathy: research to clinical practice.

Authors:  Anjali R Shah; Thomas W Gardner
Journal:  Clin Diabetes Endocrinol       Date:  2017-10-19

10.  Transforming ophthalmic education into virtual learning during COVID-19 pandemic: a global perspective.

Authors:  Irini Chatziralli; Camila V Ventura; Sara Touhami; Rhianon Reynolds; Marco Nassisi; Tamir Weinberg; Kaivon Pakzad-Vaezi; Denis Anaya; Mushawiahti Mustapha; Adam Plant; Miner Yuan; Anat Loewenstein
Journal:  Eye (Lond)       Date:  2020-07-10       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.